Working towards more effective tuberculosis (TB) vaccinations, researchers at Weill Cornell Medicine have developed two ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

The first hemophilia B patient at the Loma Linda University Health Hemophilia Treatment Center to receive Hympavzi is a ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the ...

LUCY Letby’s former boss thought that she was a “scapegoat” for the hospital’s failings and would be cleared without charge, a former chief executive has claimed. Letby, ...

Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.

The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On February 12, 2025, Fibrobiologics, Inc. (NASDAQ:FBLG) held an ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill ...

Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making ...